KA/EN
Register
Medicines reference
Search
Search
Product

Killitam

Favourites

Acepromazine · Fatro S.p.A.

1 form: tablet. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
10 mg, Tablet · Cat Cat 1/2–1 1/2 tablets per 3.5 kg
Label range: 1.5-4.5 mg/kg, stated as 0.5-1.5 tablets per 3.5 kg. The tablet calculator follows the label ratio exactly; select the intended dose within the range.
 · single administration		 single administration Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კილიტამი 10 მგ ტაბლეტები
№ 62-11
Verified on: 23 Oct 2026
10 mg, Tablet · Dog Dog 1/2–3 tablets per 10 kg
Label range: 0.5-3 mg/kg, stated as 0.5-3 tablets per 10 kg. Select a dose within the range according to the required depth of sedation; do not default to the upper limit.
 · single administration		 single administration Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კილიტამი 10 მგ ტაბლეტები
№ 62-11
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Killitam 10 mg, Tablet

acepromazine tablet for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Complete dog label: oral tranquilisation/sedation for handling, transport/motion sickness, diagnostic/procedural and preanaesthetic use, plus the listed legacy behavioural, dermatologic and anorexia claims
5.6/10
Weak evidence support
vetman assessment

Killitam

10 mg, acepromazine tablet for dogs and cats
Assessed clinical scopeDog · Complete dog label: oral tranquilisation/sedation for handling, transport/motion sickness, diagnostic/procedural and preanaesthetic use, plus the listed legacy behavioural, dermatologic and anorexia claims · By mouth
Care settingVeterinarian-selected patient-specific oral use; monitored clinic for procedural/preanaesthetic roles and responsible adult observation for any pre-visit/transport role, without automatic redosing
vetman score 5.6/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, veterinary · № 62-11 · Verified on 23 Oct 2026

An authorised, active oral tranquiliser with a strong regulatory identity but variable performance, no exact outcome programme and a broad legacy label. High labelled exposure, cardiovascular risk, absent reversal and coarse 5 mg minimum units make its practical value weak and demand conservative veterinarian-directed use.

Regulatory and scientific credibility8.5/10

Exact current Georgian and Italian/EU authorisations, a full-application basis, detailed SPC and FDA-approved same-strength oral dog-tablet control make identity and the dog endpoint highly verifiable. They do not supply Killitam bioequivalence or validate every legacy claim.

Clinical efficacy5.5/10

Acepromazine can produce oral/OTM sedation, but response is variable: an oral randomized study found only slight ataxia in 2/8 acepromazine-only dogs, while a small OTM trial showed sedation with lower pressure. Exact-product outcomes and support for the broad legacy claims are absent.

Safety and tolerability3.5/10

The 0.5-3 mg/kg label reaches far above contemporary low-dose protocols. Hypotension/collapse, hypothermia, altered haematology, prolonged or paradoxical CNS effects and absent specific reversal materially narrow use; patient, breed and ABCB1 sensitivity remain important.

Clinical practicality4.5/10

Oral use avoids injection and label onset is 40-60 minutes, but the smallest supported half is 5 mg, already 0.5 mg/kg in a 10 kg dog. The tablet is not described as scored and neither smaller fractions nor crushing are validated; response observation and recovery planning are prolonged.

Full-course cost-effectiveness-

Current Georgian per-dose price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete-scope boundary: this dog score covers every authorised Killitam tablet claim, including restraint/transport/procedural/preanaesthetic roles and legacy maternal-behaviour, neurodermatitis and nervous-anorexia claims. Acepromazine activity does not validate each claim equally.
  • Major dose/evidence conflict: the exact label gives 0.5-3 mg/kg. Contemporary studies show sedation and haemodynamic effects at much lower exposure, while an oral 2 mg/kg study produced only slight ataxia in 2/8 acepromazine-only dogs. Use a documented patient-specific plan, not automatic escalation.
  • Tablet precision: the exact SPC describes a round tablet, not a scored tablet, but gives half-tablet directions. Treat 5 mg as the smallest supported unit; do not infer quartering, crushing or dose uniformity. A half already gives 0.5 mg/kg to a 10 kg dog.
  • Assess before use: accurately weigh and evaluate temperament, previous response, hydration/perfusion, cardiovascular/hepatic/neurologic disease, age, breed and concurrent medicines. Correct hypovolaemia; reduce or avoid in shock, cardiac disease, debilitation, marked stress and old age.
  • Acepromazine is not adequate analgesia. Painful restraint, foreign-body removal, radiography positioning, minor surgery and other procedures require an independent analgesic plus appropriate local/general-anaesthetic plan; immobility does not prove comfort.
  • Monitor blood pressure, rhythm, temperature, oxygenation and recovery for procedural/preanaesthetic use. Hypotension/collapse, hypothermia, transient blood-cell sequestration, vomiting/xerostomia and prolonged depression can occur; interpret post-dose haematology accordingly.
  • No specific antagonist exists. Treat clinically important hypotension/collapse supportively with monitored veterinary care; do not use adrenaline/epinephrine for acepromazine-induced hypotension because pressure may worsen.
  • Contraindications and paradoxical response: do not use for organophosphate-poisoning tremors, hepatic dysfunction, epilepsy or hypersensitivity. Excitation, vocalisation, disorientation, aggression or convulsions can occur; never leave a first-dose patient unattended with children or animals.
  • Interactions: acepromazine potentiates general and local anaesthetics and other CNS depressants. Reduce and titrate subsequent opioid, induction, inhalant and sedative doses; review blood-pressure-lowering medicines and do not redose automatically while onset is still developing.
  • Pregnancy/lactation safety is not established; use only after veterinarian benefit-risk assessment. Store securely: accidental human ingestion can cause sedation and blood-pressure change—seek urgent medical advice and do not drive; prevent accidental animal overdose.
Assessment sources
  1. Killitam GE register2026
  2. Killitam exact SPC2024
  3. FDA oral tablet control2023
  4. GB oral acepromazine control2025
  5. AAHA anesthesia 20202020
  6. AAFP feline anesthesia2018
  7. Dog oral acepromazine trial1998
  8. Dog OTM acepromazine RCT2026
  9. Cat acepromazine RCT2021
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete cat label: oral tranquilisation/sedation for handling, transport/motion sickness, diagnostic/procedural and preanaesthetic use, plus the listed legacy behavioural, dermatologic and anorexia claims
4.6/10
Weak evidence support
vetman assessment

Killitam

10 mg, acepromazine tablet for dogs and cats
Assessed clinical scopeCat · Complete cat label: oral tranquilisation/sedation for handling, transport/motion sickness, diagnostic/procedural and preanaesthetic use, plus the listed legacy behavioural, dermatologic and anorexia claims · By mouth
Care settingVeterinarian-selected patient-specific oral use; monitored clinic for procedural/preanaesthetic roles and responsible adult observation for any pre-visit/transport role, without automatic redosing
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 62-11 · Verified on 23 Oct 2026

Exact dog/cat authorisation does not overcome the feline evidence gap: direct oral outcomes are absent, response is variable and the 1.5-4.5 mg/kg label plus a 5 mg minimum half is poorly aligned with current low-dose feline practice. The complete-label benefit-risk is weak.

Regulatory and scientific credibility7.5/10

Exact current Georgian and Italian/EU dog/cat authorisations and detailed SPC make identity highly verifiable. However, no exact-product public feline outcome dossier or current internationally authorised feline oral comparator was found.

Clinical efficacy4.0/10

Acepromazine is pharmacologically active in cats, but current evidence describes variable response and only mild combination sedation at 0.05 mg/kg. This is parenteral evidence; direct oral Killitam feline outcomes and evidence for the broad legacy claims are absent.

Safety and tolerability3.0/10

The 1.5-4.5 mg/kg oral label is extremely high relative to modern 0.01-0.05 mg/kg parenteral guidance; hypotension occurred even at 0.05 mg/kg with opioids and worsened after propofol. No specific reversal and variable feline response leave a narrow safety margin.

Clinical practicality3.5/10

Oral use avoids injection and label onset is 20-40 minutes, but the smallest supported 5 mg half is about 1.43 mg/kg in a 3.5 kg cat and cannot deliver contemporary low-dose protocols. Unvalidated smaller fractions, variable effect and monitored recovery substantially reduce practicality.

Full-course cost-effectiveness-

Current Georgian per-dose price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete-scope boundary: this cat score covers every authorised Killitam tablet claim, including restraint/transport/procedural/preanaesthetic roles and legacy maternal-behaviour, neurodermatitis and nervous-anorexia claims. Acepromazine activity does not validate each claim equally.
  • Major feline dose/evidence conflict: the exact oral label gives 1.5-4.5 mg/kg, while current AAFP parenteral guidance is 0.01-0.05 mg/kg and a 0.05 mg/kg opioid-combination trial produced only mild sedation with hypotension. Do not bridge this gap by automatic label escalation.
  • Tablet precision: the exact SPC describes a round tablet, not a scored tablet, but gives half-tablet directions. Treat 5 mg as the smallest supported unit; do not infer quartering, crushing or dose uniformity. A half gives about 1.43 mg/kg to a 3.5 kg cat.
  • Assess before use: accurately weigh and evaluate temperament, previous response, hydration/perfusion, cardiovascular/hepatic/neurologic disease, age, breed and concurrent medicines. Correct hypovolaemia; reduce or avoid in shock, cardiac disease, debilitation, marked stress and old age.
  • Acepromazine is not adequate analgesia. Painful restraint, foreign-body removal, radiography positioning, minor surgery and other procedures require an independent analgesic plus appropriate local/general-anaesthetic plan; immobility does not prove comfort.
  • Monitor blood pressure, rhythm, temperature, oxygenation and recovery for procedural/preanaesthetic use. Hypotension/collapse, hypothermia, transient blood-cell sequestration, vomiting/xerostomia and prolonged depression can occur; interpret post-dose haematology accordingly.
  • No specific antagonist exists. Treat clinically important hypotension/collapse supportively with monitored veterinary care; do not use adrenaline/epinephrine for acepromazine-induced hypotension because pressure may worsen.
  • Contraindications and paradoxical response: do not use for organophosphate-poisoning tremors, hepatic dysfunction, epilepsy or hypersensitivity. Excitation, vocalisation, disorientation, aggression or convulsions can occur; never leave a first-dose patient unattended with children or animals.
  • Interactions: acepromazine potentiates general and local anaesthetics and other CNS depressants. Reduce and titrate subsequent opioid, induction, inhalant and sedative doses; review blood-pressure-lowering medicines and do not redose automatically while onset is still developing.
  • Pregnancy/lactation safety is not established; use only after veterinarian benefit-risk assessment. Store securely: accidental human ingestion can cause sedation and blood-pressure change—seek urgent medical advice and do not drive; prevent accidental animal overdose.
Assessment sources
  1. Killitam GE register2026
  2. Killitam exact SPC2024
  3. FDA oral tablet control2023
  4. GB oral acepromazine control2025
  5. AAHA anesthesia 20202020
  6. AAFP feline anesthesia2018
  7. Dog oral acepromazine trial1998
  8. Dog OTM acepromazine RCT2026
  9. Cat acepromazine RCT2021
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Acepromazine10 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
Fatro S.P.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1335, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კილიტამი 10 მგ ტაბლეტები
№ 62-11
Verified on: 23 Oct 2026
 EU Yes, veterinary
№ 100057025 / 100057037
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Complete label: oral tranquilisation/sedation across handling, transport/motion sickness, diagnostic and procedural contexts, minor-surgery/local-anaesthesia support, pre-anaesthesia and several legacy behavioural/dermatologic/anorexia claims. Dog 0.5-3 mg/kg (0.5-3 tablets/10 kg); cat 1.5-4.5 mg/kg (0.5-1.5 tablets/3.5 kg). Start low/intermediate and assess before escalation. The exact tablet is not described as scored; half-tablet directions support 5 mg units, not smaller fractions or crushing.
DoseSpeciesWeightRouteFrequencySource
1/2–1 1/2 tablets per 3.5 kg
Label range: 1.5-4.5 mg/kg, stated as 0.5-1.5 tablets per 3.5 kg. The tablet calculator follows the label ratio exactly; select the intended dose within the range.
 Cat Any weight By mouth single administration
EU UPD Killitam 2024
Official product label (SPC), UPD, EU
Approved by an EU medicines regulator (published in the EU Union Product Database, UPD) as part of the product's authorisation. It applies to that product as authorised there.
Killitam 10 mg tablets for dogs and cats - regulatory product information
EU Union Product Database, 2024
1/2–3 tablets per 10 kg
Label range: 0.5-3 mg/kg, stated as 0.5-3 tablets per 10 kg. Select a dose within the range according to the required depth of sedation; do not default to the upper limit.
 Dog Any weight By mouth single administration
EU UPD Killitam 2024
Official product label (SPC), UPD, EU
Approved by an EU medicines regulator (published in the EU Union Product Database, UPD) as part of the product's authorisation. It applies to that product as authorised there.
Killitam 10 mg tablets for dogs and cats - regulatory product information
EU Union Product Database, 2024

Known Contraindications

  • Critical
    Do not use with hypovolaemia or dehydration.
    Sources: EU SPC
  • Critical
    Do not use with blood disorders or coagulopathy.
    Sources: EU SPC
  • Critical
    Do not use in anaemic animals.
    Sources: EU SPC
  • Critical
    Do not use with heart failure.
    Sources: EU SPC
  • Critical
    Do not use with lung failure.
    Sources: EU SPC
  • Critical
    Do not use in epileptic animals.
    Sources: EU SPC
  • Critical
    Do not use in neonates or dogs under 3 months.
    Sources: EU SPC
  • Critical
    Do not use if hypersensitive to acepromazine or excipients.
    Sources: EU SPC
  • Critical
    Do not use with hypotension or shock, in hypothermic animals or in a state of severe excitement. Organophosphates and procaine increase its toxicity.
    Sources: EU SPC
  • Warning
    MDR1 (ABCB1-1 delta) dogs: deeper, longer sedation; reduce the dose by 25-50%.
    Sources: EU SPC
  • Caution
    Liver disease or debility: use with caution at a reduced dose.
    Sources: EU SPC
  • Caution
    Safety in pregnancy not studied: benefit-risk only.
    Sources: EU SPC
  • Caution
    Safety in lactation not studied: benefit-risk only.
    Sources: EU SPC

Known Drug Interactions

  • Major warning Acepromazine + Metoclopramide
    Concomitant use with phenothiazine neuroleptics such as acepromazine or with butyrophenones increases the risk of extrapyramidal effects: agitation, ataxia, tremor, abnormal movements, vocalization, and aggression. Both agents block D2 receptors, producing an additive effect.
    Recommendation: Avoid the combination where possible. If necessary, use the lowest metoclopramide dose and monitor the animal. Effects are transient and resolve after treatment stops; there is no specific antidote, and a quiet environment is recommended.
  • Minor warning Buprenorphine + Acepromazine
    Centrally acting drugs, including tranquillisers, sedatives, and hypnotics, can increase buprenorphine-induced drowsiness. Combined use with sedatives can also increase depression of heart rate and respiration.
    Recommendation: Reduce the sedative dose during premedication; monitor heart rate and respiration.
  • Minor warning Dexmedetomidine + Acepromazine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Methadone + Acepromazine
    Methadone can potentiate analgesics, central nervous system depressants, and drugs that cause respiratory depression. Lower doses may be needed when these medicines are combined.
    Recommendation: Reduce doses when used in combination; monitor heart rate and respiration.
    Sources: Comfortan SPC

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗